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Twenty years have passed since the first reports that child-
hood acute lymphoid leukaemia was no longer incurable
(Aur, et al., 1971; Pinkel, 1971a). A combination chemo-
therapy and irradiation program consisting of 1 month of
remission induction, 1 week of intensive intravenous chemo-
therapy, 3 weeks of preventive meningeal therapy and 2 to 3
years of continuation chemotherapy resulted in lengthy leu-
kaemia-free survival in one half of the patients. Lancet (1972)
called it 'radical treatment,' but approvingly so. The purpose
of this essay is to describe some of the important lessons
about curing acute leukaemia that have been learned during
the past two decades. The lessons discussed will concern the
permanence and prevalence of cure, the cure of the child as
well as of the leukaemia, the discarding of preventive men-
ingeal irradiation, the limits of intensification of treatment,
and the importance of morphology, immunophenotype and
genotype in selection and scheduling of treatment.
Permanence and prevalence of cure
The potential permanence of cure of acute lymphoid leu-
kaemia (ALL) was established when it was demonstrated that
relapse was rare in children who experienced continuous
complete remission for 7 years and were off therapy for 4
years (Pinkel, 1979). Although the frequency of cure is less in
acute myeloid leukaemia (AML), durable complete remission
is also evident under similar circumstances (Mirro et al.,
1990). Figure 1 illustrates the event-free survival of the chil-
dren with ALL in a 1967-68 study, the first to yield a 50%
cure rate (Aur et al., 1971; Pinkel, 1987). These results have
been reproduced in numerous institutional and cooperative
group studies and there is general consensus that permanent
cures can result from modern treatment.
The more difficult issue is the prevalence of cure. National
biostatistics in the United States and the United Kingdom
indicate that childhood mortality from acute leukaemia has
been halved in the past 20 years while incidence is unchanged
(Miller & McKay, 1984; Birch et al., 1988). Therefore,
curative therapy can be assumed to be delivered to most
children with leukaemia. However, this does not appear to be
the situation in developing nations where child health care is
severely limited or services are rationed according to cost/
benefit ratio. Although accurate statistics are unavailable, it
is likely that less than 10% are cured and they are likely the
children of the more privileged. Thus, the challenge remains
to prevent childhood leukaemia or develop a simple cure if
worldwide childhood leukaemia mortality is to be signifi-
cantly affected by modern science.
Cure of the child as well as of the leukaemia
From the earliest attempts to cure childhood leukaemia
paediatricians have been concerned about cure of the child as
well as of the leukaemia. Anthropometric and neuropsy-
chological parameters, school performance and social and
work adjustment have been assessed during and after cessa-
tion of treatment. The children have been closely observed
for second cancers and organ failures that might be attrib-
uted to the leukaemia or its treatment. Efforts have been
made to establish relationships between adverse sequelae of
leukaemia and specific treatment agents in order to evaluate
the relative human cost/benefit ratios of these agents. For the
most part, children treated with conventional antimetabolite
therapy demonstrate relatively normal growth and develop-
ment, a low risk of delayed sequelae and good adjustment to
maturation.
Current information indicates that the most hazardous
agents in children with leukaemia are radiation therapy,
alkylating drugs such as cyclophosphamide, anthracyclines
such as doxorubicin, and epipodophyllotoxins such as etop-
oside. Radiation therapy produces growth inhibition and
secondary neoplasms. Cyclophosphamide causes sterility,
bladder fibrosis and carcinomas. In one report more than
one-half of children surviving ALL who had received dox-
orubicin demonstrated clinically significant cardiomyopathy 5
to 15 years later (Lipshultz et al., 1991). Etoposide and
teniposide, used in high total cumulative doses, have been
implicated in secondary acute leukaemia, often demonstra-
ting chromosomal translocations with an llq23 breakpoint
(Ratain et al., 1987).
The current therapeutic intervention in childhood leu-
kaemia exhibiting the most severe adverse sequelae is total
body irradiation (TBI), myeloablative chemotherapy and
allogeneic bone marrow transplantation (Kolb & Bender-
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Figure 1 Event-free survival, St Jude Study V. Of 35 children
with acute lymphoid leukaemia admitted to this study in
1967-68, 18 survive in initial complete remission 20 years after
cessation of treatment (Pinkel, 1989).
*From a lecture presented at the celebration of the new paediatric
oncology unit at St. Bartholomew's Hospital, London, 13 July 1990.
Received 3 June 1991; and in revised form 7 October 1991.
U .v I
Br. J. Cancer (1992), 65, 148-153 '." Macmillan Press Ltd., 1992
1-
I
-
-
n nTHERAPY OF CHILDHOOD ACUTE LEUKAEMIA 149
Gotze, 1990). All the survivors experience growth failure,
40% develop chronic graft vs host disease and 70% have
gonadal failure. Other frequent sequelae are renal, hepatic
and pulmonary insufficiency and multiple endocrine dis-
orders. The inherent problem with this modality is that all
organs and tissues are severely injured by the pre-transplant
conditioning but only one, the hematopoietic bone marrow,
is replaced. Except for the graft vs host disease, the TBI and
myeloablative chemotherapy preceding marrow autografts
result in similar sequelae.
In summary, during the past 20 years much has been
learned about the adverse sequelae of leukaemia therapy.
These can result in children cured of leukaemia, but possibly
not cured as children. They can be burdened permanently
with a legacy of growth, endocrine and neuropsychological
disturbances, organ failure and high risk for second cancers.
For this reason it is obligatory that the risks of specific
agents or modalities precluding cure of the child be weighed
carefully with their potential benefit in prolonging leukaemia-
free survival. When treatment with high risk of serious
adverse sequelae is little or no more effective than low risk
treatment, the low risk treatment needs to be chosen because
it is the more curative.
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Figure 2 Groups of DBA2 mice bearing L1210 leukaemia were
given various dosages of methotrexate (amethopterin) and their
survivals measured. Increased dosage resulted in increased sur-
vival until excessive dosage and its toxicity led to shortened
survival (Goldin et al., 1956).
Discarding preventive meningeal irradiation
One of the key features of successful curative therapy 20
years ago was meningeal irradiation, with or without intra-
thecal chemotherapy, to prevent primary meningeal relapse
(Aur et al., 1971). Its value was demonstrated in a ran-
domised comparative study initiated shortly after a pilot
study suggested it. However, a subsequent comparative study
by the Paediatric Oncology Group (POG) revealed that a
three drug combination ofmethotrexate, hydrocortisone, and
cytarabine, injected intrathecally during remission induction
and periodically during the next 2 years of continuation
chemotherapy, was therapeutically equivalent to cranial irra-
diation and intrathecal methotrexate (Sullivan, et al., 1982).
In a recent POG pilot study in which intermediate high dose
methotrexate and cytarabine were administered as well as
three drug intrathecal therapy, only three of 99 patients
developed primary meningeal relapse (Krance et al., 1991). In
the last 5 years of experience at M.D. Anderson Cancer
Center there has been no instance of isolated primary men-
ingeal relapse in children with acute leukaemia who received
intrathecal therapy and intermediate high dosage intravenous
chemotherapy.
In conclusion, meningeal irradiation with its consequent
risks of neuropsychological, growth and neoplastic sequelae,
can be omitted when appropriate systemic and intrathecal
chemotherapy are utilised.
The limits of intensification of treatment
An important lesson learned in the past 20 years is the
self-limiting therapeutic value of increasing the number and
dosage of anti-leukaemia agents. Goldin and his colleagues
first demonstrated the practical limits of treatment
intensification in leukaemia (Figure 2) (Goldin et al., 1956).
Their experiments, using a transplantable leukaemia in in-
bred mice, showed that increasing the dosage ofmethotrexate
improved survival up to a certain point, beyond which there
was progressive shortening of survival with serial increases.
There was an optimal dosage of drug above which
therapeutic effect was surpassed by toxic effect.
A late 1960's study in children with ALL demonstrated
that full, more toxic dosage combination chemotherapy re-
sulted in longer remissions than half, less toxic dosage
(Pinkel et al., 1971b). The need for 'maximum tolerable
dosage' was emphasised, therefore, in the curative treatment
programs that followed. However, in a 1972-75 study, child-
ren with ALL who received two drugs at maximum tolerable
dosage had a better chance of surviving in complete remis-
sion than those receiving three or four drugs (Figure 3) (Aur
et al., 1978). Although the numerical difference was
insufficient to be statistically significant, the results suggested
that intensification of chemotherapy by use of more drugs
might be nonproductive, especially if the additional drugs
were less effective and their toxicity overlapped with that of
the more effective agents, thus inhibiting their dosage.
Non-comparative studies of ALL have been described in
which better remission experience is claimed for use of multi-
ple drugs, including anthracyclines and alkylating agents,
rather than simpler antimetabolite regimens (reviewed by
Rivera & Mauer, 1987). However, the claims are based
largely on historical comparisons, it is not clear whether the
patients on the simpler regimens received maximum tolerable
dosage, and the impact of self-exclusion of patients who are
sicker, poorer or less nourished from the multiple drug
regimens is not quantitated. On the other hand, the POG
8205, 8399 and 8602 studies focus on optimal dosage of
antimetabolites (methotrexate, mercaptopurine, cytarabine),
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Figure 3 Children with acute lymphoid leukaemia were rando-
mised to one offour treatment regimens after remission induction
and preventive meningeal therapy. Those receiving methotrexate
and mercaptopurine experienced better leukaemia-free survival
than those receiving additional drugs (Aur et al., 1978).
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largely administered parenterally and in intermediate high as
well as conventional dosage; they exclude anthracyclines,
alkylating agents and radiation (Camitta et al., 1989; Land et
al., 1989; Krance et al., 1991). These studies have yielded
therapeutic results historically comparable to those of the
more extensive multiple drug regimens, but without the
liability of their potential adverse sequelae.
In summary, there is currently no information to indicate
that maximum tolerable dosage of antimetabolite therapy, as
currently administered, is of less efficacy in ALL than more
extensive multiple drug regimens. However, as indicated fur-
ther on in this review, this may only be true for the
predominating B-precursor ALL of childhood.
In the case of acute nonlymphoid leukaemia, the limits of
treatment intensification are more apparent. In three con-
secutive treatment protocols at one leukaemia center the
dosage and number of drugs and the consequent toxicity
were markedly increased (Figure 4a) (Mirro et al., 1990).
However, the plateaus of continuous complete remission for
children who received relatively simple, nontoxic, outpatient
treatment in earlier years are not significantly different from
those who were given complex, highly toxic inpatient-based
treatment more recently. The results of consecutively more
intense POG treatment programs are strikingly similar (Fig-
ure 4b) (Steuber et al., 1990). Although higher remission
induction rates improved short term survival, long term
leukaemia-free survival remains approximately the same.
The ultimate in intensification of leukaemia therapy is
myeloablative chemotherapy, usually accompanied by lethal
TBI, followed by allogeneic, mismatched, or autologous bone
marrow transplantation. Again, there appears to be no
therapeutic advantage of this method over present current
combination chemotherapy regimens that bear considerably
less cost in adverse sequelae (Pinkel, 1989a). This has been
demonstrated for ANLL in first remission in children and
young adults (Figure 5) (Dahl et al., 1990; Geller et al., 1990;
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Figure 5a The lengthy complete remission experience of children
with acute myeloid leukaemia in first remission was not signifi-
cantly different for allogeneic marrow transplants vs chemother-
apy alone (Dahl et al., 1990). b, Young adults in first remission of
acute myeloid leukaemia had similar cure rates whether treated
with chemotherapy-conditioned allogeneic marrow transplants or
intensive chemotherapy alone (Geller et al., 1990).
Schiller et al., 1990) and for ALL in first remission in child-
ren and young adults (Figure 6) (Chessels et al., 1990;
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Figure 4a Increasing number and dosage of drugs were used in
treatment programs for children with acute myeloid leukaemia at
St Jude Children's Research Hospital from 1976 to 1986. The
consequence was greater toxicity and more hospitalisation with-
out improvement in cure rate (Mirro et al., 1990). b, Consecutive
treatment regimens of the Paediatric Oncology Group for child-
ren with acute myeloid leukaemia show similar cure rates despite
improvements in short term survival (Steuber et al., 1990).
The importance ofmorphology, immunophenotype and
genotype in selection and scheduling of treatment
Early in the development of chemotherapy of acute leu-
kaemia it became apparent that acute myeloid leukaemia
(AML) was less responsive to prednisone, methotrexate and
mercaptopurine than ALL. When daunorubicin and cytosine
arabinoside became available and were found to be highly
effective for inducing remission of AML, it became apparent
that morphology was a key determinant in selection of anti-
leukaemia drugs. In the 1970's it became standard practice to
use different treatment protocols for AML vs ALL. Among
the morphological subtypes of AML, the monocytoid and
myelomonocytoid varieties appeared to be more sensitive to
the epipodophyllotoxins, etoposide and teniposide.
In 1975 thymic precursor ALL was identified as a distinct
clinical and biological subclass ofmorphological ALL, assoc-
iated with short remissions and a low cure rate when treated
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Figure 6 Leukaemia-free survival (LFS) in young German adults
with acute lymphoid leukaemia was similar whether treated with
chemotherapy alone or myeloablation and allogeneic marrow
transplant (Horowitz et al., 1991).
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trial demonstrated that children with thymic ALL who re-
ceived cyclophosphamide and cytarabine in addition to meth-
otrexate and mercaptopurine had a superior cure rate while
those with non-thymic ALL did not (Figure 8) (Lauer et al.,
1987). Reports concerning B cell lymphoma and B cell ALL
have emphasised the prime importance of cyclophosphamide in this disorder. Currently, the POG and others utilise
separate treatment protocols for T cell, B cell and B precur-
sor ALL, verifying the significance of immunophenotype in
selection and scheduling of ALL therapy.
The importance of genotype in selecting treatment was
recognised in the same way as the significance ofmorphology and immunophenotype had been identified earlier. Children
with pseudodiploid ALL, with chromosomal translocations,
particularly t(l;19), t(4;11) and t(9;22), in their leukaemia cell
metaphases, were noted to have shorter remissions and a
lower cure rate (Pui et al., 1988). On the other hand, those
with hyperdiploid ALL, with chromosome numbers above 50
and/or a DNA index greater than 1.16 in their leukaemia
cells, had superior remission durations and cure rates on the
same treatment regimens. These observations and others led
to the hypothesis that antileukaemia drugs should be selected
according to genotype (Pinkel, 1987). Supporting this
hypothesis are the following: acute leukaemias are genetic disorders of hematopoiesis; their morphology and immuno-
phenotype are reflections of these genetic disorders; the
curative antileukaemia agents generally act through modification of DNA synthesis and structure; cure of acute
leukaemia results in eradication of the genetically disordered
leukaemia cells but not the genetically normal hematopoietic
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Figure 7a Second remissions of acute lymphoid leukaemia in
children treated with chemotherapy depended on duration of first
remission (Rivera et al., 1986). first remission ) 18 months;
--- first remission < 18 months). b, Remission experience of
comparable children who received myeloablation and purged
marrow autografts was no different (Sallan et al., 1989).
according to standard protocols for ALL (Sen & Borella,
1975). The hypothesis was proposed that immunophenotype
might be a determinant of chemotherapy sensitivity of ALL
and a criterion for selection of drug treatment (Pinkel, 1979).
This hypothesis was supported by studies in mice which
demonstrated that thymic leukaemia was more sensitive to
cyclophosphamide and cytarabine than methotrexate and
mercaptopurine (Frei et al., 1974). A comparative clinical
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Figure 8a Children with non-T lymphoid leukaemia were not
benefited by addition of cyclophosphamide and cytarabine to
their continuation chemotherapy (Lauer et al., 1987). b, For
T-cell lymphoid leukaemia, only children who received cyclophos- phamide and cytarabine remained in remission (Lauer et al.,
1987).
C ()
cu
._
0
C
0
0
._
0
0 E- w
U) UJ-
o,~
(0.
. 0
O4C
a0)
I
- * * 5 * u * * * * a m
3
I I I152 D. PINKEL
cells of similar morphology and immunophenotype. Further
support for this concept is the observation that acute pro-
myeloid leukaemia with the 15;17 translocation and aberrant
messenger RNA for retinoic acid receptor alpha is uniquely
responsive to all trans retinoic acid, albeit through a
differentiation mechanism (Huang et al., 1988; de The et al.,
1990). In pilot studies described elsewhere the idea that
genotype may be the most important criterion of selecting
and scheduling antileukaemia drugs is being explored (Pinkel,
1989b). A new POG phase 3 comparative study of B precur-
sor ALL uses hyperdiploidy, as indicated by DNA index, to
stratify patients.
However, none of these features - morphology, immuno-
phenotype or genotype - completely explain differences in
curability with specific treatment regimens. Some children
with hyperdiploid B precursor ALL experience relapse after
treatment that is curative for the vast majority with similar
disease. On the other hand, some children with ALL who
have translocations associated with poor outcome are cured
with treatment that is unsuccessful in most children with the
same findings. Obviously, there are important factors in
selecting therapy that are yet to be determined.
Summary
The past 20 years of curative therapeutics of childhood acute
leukaemia has been largely a period of consolidation of
gains, refinement of techniques and dissemination of exper-
tise and technology. However, certain lessons have been
learned. First, cure can be permanent but the complexity and
cost of curative treatment currently restricts its accessibility;
prevention or simple curative treatment is needed.
Secondly, cure of the child demands that the risk of
adverse sequelae of treatments be carefully balanced with
known therapeutic benefits. Thirdly, preventive meningeal
irradiation is no longer required. Fourth, treatment
intensification is self-limiting. Adverse reactions can cancel
out or exceed therapeutic benefits, resulting in a lower cure
rate or a similar cure rate with lower quality ofcure. Finally,
morphology, immunophenotype and genotype of acute
leukaemia are important criteria for selecting and scheduling
drug therapy. Genotype may be the most important since
leukaemia is a genetic disorder for which morphology and
immunophenotype are mere reflections. However, none of
these features, individually or together, are sufficient to ex-
plain all the difference in outcome among children on a given
treatment plan or to completely fulfill the need of criteria for
selection of treatment.
Acute leukaemia remains an unsolved problem demanding
considerably more basic and clinical research to meet the
need for prevention and simple dependable curative treat-
ment.
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